Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
06 May 2019 FDA Approves Ivosidenib as First-Line Treatment for AML with IDH1 Mutation Haematologic malignancies - Cancer in Special Situations / Population - Personalised medicine - Anticancer agents & Biologic therapy
04 May 2019 Patients aged 75-79 years at higher risk of distant recurrence than patients aged 70-74 years in the older population (>70 years) of patients with early stage breast cancer despite higher competing mortality Breast cancer - Cancer in Special Situations / Population
03 May 2019 EMA Recommends an Extension of Therapeutic Indication for Olaparib Gynaecologic malignancies - Personalised medicine - Anticancer agents & Biologic therapy
02 May 2019 De-escalation of Commonly Used Bone-Treating Agents Is A Reasonable Treatment Option for Patients with Bone Metastases from Breast Cancer Breast cancer - Palliative and supportive care
02 May 2019 Molecular Analysis of Samples from the AURORA Programme Is Underway Breast cancer - Translational research
30 Apr 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Cemiplimab Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
29 Apr 2019 EMA Recommends Withdrawal of Marketing Authorisation for Olaratumab Sarcomas - Anticancer agents & Biologic therapy
26 Apr 2019 EMA Recommends Granting a Marketing Authorisation for Talazoparib Breast cancer - Personalised medicine - Anticancer agents & Biologic therapy
25 Apr 2019 Ovarian Cancer Organoids Gynaecologic malignancies - Translational research
24 Apr 2019 A Spotlight on Precision Cancer Medicine Personalised medicine
23 Apr 2019 FDA Approves Pembrolizumab Plus Axitinib for Advanced Renal Cell Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
16 Apr 2019 EMA Starts New Review of Risks with High-strength Estradiol-containing Creams Gynaecologic malignancies - Epidemiology/Etiology/Cancer Prevention
15 Apr 2019 FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma Genitourinary cancers - Personalised medicine - Anticancer agents & Biologic therapy
12 Apr 2019 FDA Expands Pembrolizumab Indication for First-line Treatment of NSCLC (TPS ≥1%) Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
11 Apr 2019 First-line Durvalumab Improves Survival Compared to Chemotherapy in Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy